Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Allergy & Immunology
•
Pulmonology
•
Diffuse Parenchymal Lung Disease
•
Primary Immunodeficiency
How often are you performing CT screening in CVID patients to screen for ILD?
Answer from: at Academic Institution
CT once every 1-2 years, depending on symptoms and PFTs. PFTs, including DLCO, are annually performed.
Sign In
or
Register
to read more
30257
Related Questions
Are there certain clinical features that help you choose between benralizumab and mepolizumab for EGPA in clinical practice?
Do you utilize cytokine panels to guide treatment of patients with EGPA?
Are there benefits to adding IL5/IL5 receptor blockade in patients with vasculitic manifestations of EGPA?
How frequently do you monitor CT scans, PFTs, and TTEs in patients with ILA or mild ILD?
Is there any indication for IVIG in immunocompromised patients with only decreased IgM and/or IgA levels?
Do you seek pathologic confirmation before proceeding with empiric immunosuppressive therapy in symptomatic patients with radiographic NSIP?
What are your thoughts on using abatacept for RA-associated ILD in a patient undergoing treatment for CLL with zanubrutinib, and how would you assess the potential increased risk of infection in this context?
Is it still significant to denote the etiology of ILD in a patient with PPF?
What factors would encourage you to choose abatacept vs tocilizumab in a patient with RA-ILD with a UIP pattern of pulmonary fibrosis?
How do you manage pleuroparenchymal fibroelastosis in a patient with seronegative RA that is progressing on Rituxan and DMARD therapy?